seeing green

Houston company focused on renewables sees high growth potential amid 'energy revolution'

According to Houston-based ENGlobal, the company "has more promising opportunities for significant new business than at any time in [the] company's history." Photo via Getty Images

For Houston-based ENGlobal Corp., a provider of engineering and automation services geared toward the energy industry, renewable fuel facilities are a business pipeline gushing with opportunity.

ENGlobal's potential contracts for renewable fuels projects currently exceed $320 million, says Bill Coskey, the company's founder, president, and CEO. That's about six times the amount of ENGlobal's revenue through the first nine months of this year — $52.9 million.

During the company's third-quarter earnings call November 5, Coskey said publicly traded ENGlobal "has more promising opportunities for significant new business than at any time in our company's history."

Many of those opportunities stem from ENGlobal's shift a couple of years ago to a sharp focus on the renewable energy sector. This includes building utility-scale systems to store wind and solar power, and supplying modular engineered process plants for forms of energy like hydrogen and renewable diesel. Modular process plants consist of separately engineered and automated modules that are made off-site and assembled on-site.

"Manufacturing plants based on modular equipment are emerging as a viable and beneficial alternative to conventional stick-built processing plants. Modular equipment offers several benefits, including flexibility in plant siting, fewer safety concerns during construction, and ease of equipment modification," according to the American Institute of Chemical Engineers.

ENGlobal is engineering and fabricating a modular hydrogen plant for a renewal diesel facility scheduled for completion in May. Incorporating proprietary technology from Denmark-based Haldor Topsoe (which has two offices and one plant in the Houston area), this hydrogen plant will consume about 20 percent less feed and fuel than conventional hydrogen plants, leading to lower operating costs and a smaller carbon footprint. It's the first facility of its kind in the U.S. This $25 million project falls into a bucket of modular process plants — valued at $10 million to $200 million each — that ENGlobal typically pursues.

ENGlobal's emphasis on renewable energy is paying off, especially now. That's because this sector is less susceptible to economic harm caused by the coronavirus pandemic and to the downturn in the oil and gas industry, according to Coskey.

"To the contrary, the green and renewable energy sector is driven by a different set of project economics — the majority of which play directly to our core strengths and capabilities," Coskey said during the November 5 earnings call.

ENGlobal comprises two business units that are capitalizing on those core strengths and capabilities:

  • Engineering, procurement, and construction management
  • Automation

Through September 26, the automation segment of the business accounted for 63 percent of the company's revenue this year, with engineering, procurement, and construction at 37 percent. In the third quarter, the balance was roughly 50-50.

For the nine-month period ended September 26, ENGlobal posted a 33 percent increase in revenue compared with the same period a year earlier. Revenue for the period rose 37 percent in the automation segment of the business and 27 percent in the engineering, procurement, and construction management segment.

Looking ahead, Coskey says plants like the one employing the Haldor Topsoe technology are "a big area of growth for us."

"We've built a business which is really vertically integrated. We can engineer and design, we can mechanically fabricate the processing modules, we can automate them, we can go onto the site and start them up. So we have full-service capabilities," Coskey says in an interview.

Those capabilities are helping ENGlobal, which Coskey started in 1985, capitalize on what he dubs the "energy revolution" in the U.S.

"Oil and gas has a long runway and is sometimes not given enough credit," he says. "But I can tell you that the capital spending for traditional oil and gas projects pretty much dried up during the course of this year. And we had to look for other sources of work for our people, so we were fortunate to have these renewable energy projects to work on."

Evercore ESI predicts capital spending on energy exploration and production in the U.S. will fall 43 percent this year compared with 2019. Meanwhile, S&P Global Market Intelligence forecasts $14.26 billion in capital spending this year on renewable energy by major U.S. utilities, up more than 20 percent from an earlier projection for 2020. The share of U.S. electricity generation from renewable energy is expected to increase from 18 percent in 2019 to 20 percent this year and 21 percent in 2021, the U.S. Energy Information Administration says.

"There's a lot of money that used to flow into oil and gas projects that now seems to be flowing into renewable energy projects," Coskey says. "We were lucky to identify that early and be positioned to capture some of that."

Trending News

Building Houston

 
 

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Trending News